Nevertheless, in BC patients with low CD8+ T cells, the evaluation of the TMB is not only uninformative of ICI benefit, but can even be associated with ICI-resistance [32], as the antigens produced by cancer cells must be somehow presented to the immune system to elicit an immune response. The gene discussed is CD8A; the disease is breast cancer.